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The impact of hepatic steatosis on interferon therapy for patients with chronic hepatitis C (CHC) has 
been associated with single-nucleotide polymorphisms (SNP) of IL28B,  patatin-like phospholipase 
domain-containing protein 3 (PNPLA3),  and low-density lipoprotein (LDL) receptor.  Whether this holds 
true for Japanese patients,  however,  remains unresolved.  The present study prospectively enrolled 
226 Japanese patients with CHC,  and investigated the impact of hepatic steatosis and its related SNPs,  
including rs8099917 of IL28B,  rs738409 of PNPLA3,  and rs14158 of LDL receptor,  on outcomes of peg-
interferon and ribavirin therapy.  In multivariate logistic regression analysis,  signiﬁcant factors 
aﬀecting the severity of hepatic steatosis were high body mass index and the minor alleles of IL28B 
SNP (p＝0.020 and 0.039,  respectively).  The risk alleles of PNPLA3 SNP also showed weak associa-
tion (p＝0.059).  Severe steatosis and the minor alleles of IL28B SNP were signiﬁcantly associated with 
null or partial virological response in patients with HCV genotype 1,  as were female gender,  and low 
LDL cholesterol (p＝0.049,  and ＜0.001,  respectively).  The SNP genotype of PNPLA3 and LDL recep-
tor did not have a signiﬁcant impact on therapeutic outcomes.  With respect to the SNP sites examined,  
the SNP of PNPLA3 has a weak association with severe hepatic steatosis,  but not with the outcome of 
interferon therapy.
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epatitis C virus (HCV) infection causes chronic 
hepatitis,  and may progress to liver cirrhosis 
and hepatocellular carcinoma.  More than 170 million 
people worldwide are infected with HCV,  creating a 
serious global health problem [1].  Combination therapy 
with pegylated interferon-α (PegIFN) and ribavirin 
(RBV) achieves a sustained virological response (SVR) 
in more than 50ｵ of patients with HCV genotype 1 
[2].  Recent therapeutic regimens using direct-acting 
antiviral agents have improved therapeutic outcomes 
for HCV patients,  achieving an SVR of up to 80ｵ 
[3-5].  Null or partial virological responders still 
exist,  however,  due to drug-resistant viruses or other 
causes [6-8].
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　 Single-nucleotide polymorphisms (SNPs) near the 
IL28B gene are signiﬁcantly associated with therapeu-
tic outcomes for patients with HCV genotype 1 [9].  
In addition,  older age,  female gender,  advanced liver 
ﬁbrosis,  and hepatic steatosis aﬀect therapeutic out-
comes.  Recently,  signiﬁcant associations have been 
found between hepatic steatosis and ﬁbrosis and the 
SNP of rs738409 in the patatin-like phospholipase 
domain-containing protein 3 (PNPLA3) in patients 
with fatty liver disease,  alcoholic liver disease,  and 
chronic hepatitis C [10,  11].  The impact of this SNP 
on therapeutic outcomes of PegIFN and RBV has been 
reported for patients with chronic hepatitis C (CHC).  
These results were mostly obtained from the analysis 
of Caucasian patients [12,  13],  however,  and their 
applicability to Japanese patients remains uncertain.  
When human immunodeﬁciency virus (HIV)/HCV co-
infected patients received IFN therapy with PegIFN 
and RBV,  the SNP of rs14158 in the low-density 
lipoprotein (LDL) receptor may have aﬀected thera-
peutic outcomes in patients with the major allele of 
IL28B SNP [14].  Furthermore,  the association of 
this SNP with therapeutic outcome has not been 
clariﬁed for HCV mono-infected patients.
　 The present study investigated the impacts of 
hepatic steatosis and its related SNPs on the out-
comes of PegIFN and RBV therapy for Japanese 
patients with CHC.
Methods
　 Patients. This study was a prospective analy-
sis of 226 Japanese CHC patients who received anti-
viral therapy with standard doses of PegIFN alpha-2a 
or 2b with RBV between 2005 and 2010 at Okayama 
University Hospital or Kagawa Prefectural Central 
Hospital.  Hepatocellular carcinoma was ruled out with 
dynamic computed tomography or magnetic resonance 
imaging,  in combination with serum alpha-fetoprotein.  
Patients with hepatitis B virus co-infection,  HIV co-
infection,  or autoimmune liver disease were not 
included in the study.  The study was performed in 
accordance with the Helsinki Declaration,  and the 
protocols were approved by the ethics committees of 
the participating institutions.  All patients provided 
informed consent before enrollment into the study.
　 Diagnosis of liver histology. Liver histology 
was evaluated for all patients prior to the start of 
therapy.  Patientsʼ histological ﬁbrosis stage and hepa-
titis activity grade were assigned by 2 pathologists 
according to the criteria outlined in Desmet et al.  
[15].  The severity (grade) of hepatic steatosis was 
deﬁned according to the criteria used by Valenti et al.  
[13].  Hepatic steatosis occupying less than 5ｵ of the 
quadrant in the liver was classiﬁed as no steatosis;  
steatosis occupying 5ｵ to less than 30ｵ was classi-
ﬁed as mild; and steatosis occupying 30ｵ or more of 
the quadrant was considered severe.
　 Genotyping of single nucleotide polymor-
phisms. Genomic DNA was extracted from whole-
blood samples by means of a QIAamp DNA Mini Kit,  
according to the manufacturerʼs protocol (Qiagen,  
Tokyo,  Japan).  The SNPs rs8099917 of IL28B,  
rs738409 of PNPLA3,  and rs14158 of LDL recep-
tors were genotyped using the TaqMan predesigned 
SNP genotyping assays in a LightCycler 480 system,  
as recommended by the manufacturer (Roche Diag-
nostics,  Tokyo,  Japan).  The SNP genotypes of all the 
samples were obtained with these systems.
　 Statistical analysis. Data are expressed as the 
mean ± standard deviation.  Correlations between 
patient laboratory data and histological ﬁndings were 
evaluated using the Chi-square test and Spearmanʼs 
rank correlation coeﬃcient.  Factors associated with 
the presence and severity of hepatic steatosis,  or the 
patient characteristics associated with therapeutic 
outcome,  were analyzed by logistic regression,  and 
selected in a stepwise manner among the signiﬁcant 
factors in univariate analysis for the multivariate 
analysis.  A value of p＜0.05 was considered signiﬁ-
cant.  Statistical analysis was performed with JMP 
software (SAS Institute,  Cary,  NC,  USA).
Results
　 Relation between patient characteristics and 
hepatic steatosis. As shown in Table 1,  hepatic 
steatosis was classiﬁed as severe for 34 patients,  mild 
for 92 patients,  and as none for 99 patients.  We 
compared patient characteristics at enrollment among 
these three steatosis-severity groups.  Body mass index 
(BMI),  serum triglyceride levels,  and homeostasis 
model assessment insulin resistance (HOMA-IR) were 
signiﬁcantly associated with severity of hepatic steato-
sis (p＜0.001,  0.029,  and 0.0026,  respectively;  
Spearmanʼs rank correlation coeﬃcient).  Severe 
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hepatic steatosis was signiﬁcantly associated with 
advanced ﬁbrosis stages and the minor alleles (TG or 
GG) of IL28B SNP (p＜0.001,  and 0.0024,  respec-
tively).  The patients with the risk alleles (GC or GG) 
of PNPLA3 SNP showed a slight tendency toward an 
association with severe hepatic steatosis (p＝0.055),  
while the SNP genotypes of LDL receptor were not 
associated with severity of hepatic steatosis (p＝0.77).  
Distributions of age,  sex,  and HCV genotype did not 
diﬀer signiﬁcantly according to severity of hepatic 
steatosis.
　 Diﬀerences in the relation of the associated 
factors to the presence and severity of hepatic 
steatosis. Table 2 shows the results of stepwise 
logistic regression analysis for the association of 
patient characteristics with the presence or severity 
of hepatic steatosis.  Advanced ﬁbrosis stages were 
signiﬁcantly associated with the presence of hepatic 
steatosis (p＝0.0052),  but not with its severity.  Higher 
BMI was signiﬁcantly associated with both the pres-
ence and the severity of hepatic steatosis (p＜0.001,  
and 0.020,  respectively).  In contrast,  the minor 
alleles of IL28B SNP showed a strong association 
with the severity but not the presence of hepatic ste-
atosis (p＝0.0039).  Patients with the risk alleles of 
PNPLA3 SNP showed a slight tendency toward an 
association with severe hepatic steatosis (p＝0.059).
　 The impact of hepatic steatosis and its related 
SNPs on IFN therapeutic outcomes. As for 
associations between the presence or severity of 
hepatic steatosis and therapeutic outcomes,  SVR was 
not signiﬁcantly associated with the presence or 
severity of hepatic steatosis (Odds 0.69,  p＝0.14,  
and Odds 0.63,  p＝0.22,  respectively,  by logistic 
regression analysis),  while NVR was signiﬁcantly 
associated with the severity,  but not the presence of,  
hepatic steatosis (Odds 3.2,  p＝0.0034,  and odds 1.7,  
p＝0.11,  respectively).  Among the patients with a 
null or partial virological response (NVR),  a greater 
percentage had severe hepatic steatosis (41.2ｵ) than 
no or mild steatosis (16.5ｵ and 19.6ｵ,  respectively,  
p＝0.0033).  The association of hepatic steatosis and 
its related SNPs to therapeutic outcomes were fur-
ther analyzed separately for patients with HCV geno-
types 1 and 2,  because these patient groups were 
treated with diﬀerent IFN regimens.  Among the 
patients with HCV genotype 1,  63 patients (41.1ｵ) 
obtained SVR,  while 44 (28.8ｵ) obtained a null or 
partial response.  Early liver ﬁbrosis stages and the 
major allele of IL28B SNP were signiﬁcantly associ-
ated with SVR for the patients with HCV genotype 1 
(p＝0.0055 and 0.024; stepwise logistic regression 
analysis,  Table 3).  The minor alleles of IL28B SNP,  
female gender,  low levels of LDL cholesterol,  and 
severe hepatic steatosis were signiﬁcant predictors for 
NVR (p＝0.0001,  0.011,  0.006,  and 0.049,  respec-
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Table 1　 Patient characteristics and the severity of hepatic steatosis at enrollment
Severity of hepatic steatosis
None (n＝99) Mild (n＝92) Severe (n＝34) P
Age (years) 57±10‡ 58±9‡ 58±10‡ 0.46
Sex (male/female) 49/50 47/45 15/19 0.78
Body mass index 23±3‡ 24±3‡ 25±4‡ 0.0002
Liver ﬁbrosis (F1/F2/F3/F4) 46/38/11/3 27/35/23/7 11/8/14/1 0.0008
Hepatitis activity (A1/A2/A3) 77/19/2 68/19/3 19/14/1 0.069
IL28B (TT/TG/GG) 78/20/1 78/14/0 19/14/1 0.0024
PNPLA3 (CC/GC/GG) 23/50/26 27/46/19 3/22/9 0.055
LDL receptor (GG/GA/AA) 38/42/19 36/40/16 11/13/10 0.77
HCV genotype (1/2) 69/30 70/22 22/12 0.94
ALT (IU/L) 61±63‡ 74±55‡ 67±36‡ 0.0089
γGT (IU/L) 48±49‡ 57±53‡ 71±56‡ 0.0003
LDL cholesterol (mg/dL) 102±29‡ 99±24‡ 96±32‡ 0.17
Triglyceride (mg/dL) 106±52‡ 113±53‡ 136±93‡ 0.029
HOMA-IR 4.3±8.8‡ 4.6±8.8‡ 4.5±6.1‡ 0.0026
‡Mean±standard deviation.  PNPLA3,  patatin-like phospholipase domain-containing protein 3; LDL,  low-density lipoprotein; ALT,  ala-
nine aminotransferase; γGT,  γ-glutamyl transpeptidase; HOMA-IR,  homeostasis model assessment insulin resistance.
tively).  Unlike in the report for patients co-infected 
with HCV genotype 1 and HIV [14],  the minor allele 
of rs14158 in the LDL receptor did not aﬀect thera-
peutic outcomes among the patients with the major 
allele of IL28B SNP (p＝0.83); the prevalence of the 
minor allele of LDL receptor SNP was 58ｵ among 
the patients with SVR (35/60),  66ｵ among those with 
transient virological response (TVR,  29/44),  and 59ｵ 
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Table 2　 Logistic regression analysis of the factors related to the presence or severity of hepatic steatosis
Analysis for presence of steatosis Analysis for severity of steatosis
Univariate Multivariate Univariate Multivariate
Factors Odds (range†) p Odds (range†) p Odds (range†) p Odds (range†) p
Age 1.0 (0.98-1.0) 0.41 1.0 (0.97-1.1) 0.57
Sex (male＝1) 1.0 (0.58-1.7) 0.97 0.78 (0.38-1.6) 0.51
Body mass index 1.2 (1.1-1.3) 0.0003 1.2 (1.1-1.3) 0.0005 1.1 (1.1-1.3) 0.0049 1.2 (1.0-1.3) 0.020
Liver ﬁbrosis 1.7 (1.3-2.4) 0.0007 1.6 (1.2-2.3) 0.0052 2.6 (0.92-2.0) 0.13
Hepatitis activity 1.3 (0.81-2.2) 0.26 1.9 (1.0-3.5) 0.047 1.6 (0.79-3.2) 0.20
IL28B (TT＝1) 0.9 (0.48-1.7) 0.75 0.28 (0.13-0.61) 0.0014 0.37 (0.15-0.95) 0.039
PNPLA3 (CC＝1) 1.0 (0.56-1.9) 0.92 0.27 (0.08-0.93) 0.038 0.29 (0.081-1.0) 0.059
LDL receptor (GG＝1) 0.96 (0.56-1.6) 0.77 0.76 (0.35-1.6) 0.48
Genotype (type 1＝1) 1.2 (0.66-2.1) 0.58 0.69 (0.32-1.5) 0.34
ALT 1.0 (1.0-1.0) 0.18 1.0 (0.99-1.0) 0.99
γGT 1.0 (1.0-1.0) 0.052 1.0 (1.0-1.0) 0.70 1.0 (1.0-1.0) 0.089 1.0 (1.0-1.0) 0.44
LDL cholesterol 1.0 (0.99-1.0) 0.32 0.94 (0.98-1.0) 0.31
Triglyceride 1.0 (1.0-1.0) 0.16 1.0 (1.0-1.0) 0.029 1.0 (1.0-1.0) 0.19
HOMA-IR 1.0 (0.99-1.0) 0.49 0.99 (0.97-1.0) 0.59
†95% conﬁdence interval; PNPLA3,  patatin-like phospholipase domain-containing protein 3; LDL,  low-density lipoprotein; ALT,  alanine 
aminotransferase; γGT,  γ-glutamyl transpeptidase; HOMA-IR,  homeostasis model assessment insulin resistance.
Table 3　 Logistic regression analysis of the factors related to the therapeutic outcomes of interferon therapy for the patients with HCV 
genotype 1
Analysis for sustained virological response Analysis for non-virological response
Univariate Multivariate Univariate Multivariate
Factors Odds (range†) p Odds (range†) p Odds (range†) p Odds (range†) p
Age 0.95 (0.92-0.99) 　0.0064 0.97 (0.93-1.0) 0.12 1.1 (1.0-1.1) 　0.0036 1.1 (0.99-1.1) 0.084
Sex (male＝1) 1.4 (0.73-2.6) 　0.32 0.51 (0.25-1.0) 　0.065 0.27 (0.094-0.74) 0.011
Body mass index 1.0 (0.92-1.1) 　0.70 1.0 (0.92-1.1) 　0.73
Liver ﬁbrosis 0.44 (0.29-0.66) ＜0.0001 0.50 (0.31-0.82) 0.0055 1.6 (1.1-2.4) 　0.018 1.4 (0.77-2.5) 0.28
Hepatitis activity 0.81 (0.45-1.5) 　0.48 1.2 (0.64-2.2) 　0.59
Hepatic steatosis 0.50 (0.24-0.87) 　0.18 1.8 (0.88-3.8) 　0.11
Severe steatosis 0.76 (0.47-1.2) 　0.27 2.2 (1.4-3.6) 　0.0009 1.9 (1.0-3.7) 0.049
IL28B (TT＝1) 2.8 (1.2-6.8) 　0.019 3.6 (1.2-11) 0.024 0.11 (0.045-0.25) ＜0.0001 0.077 (0.021-0.28) 0.0001
PNPLA3 (CC＝1) 0.72 (0.34-1.5) 　0.40 1.3 (0.58-2.8) 　0.54
LDL receptor (GG＝1) 1.2 (0.61-2.2) 　0.66 1.1 (0.52-2.2) 　0.88
ALT 1.0 (1.0-1.0) 　0.28 1.0 (0.99-1.0) 　0.80
γGT 1.0 (1.0-1.0) 　0.36 1.0 (1.0-1.0) 　0.25
LDL cholesterol 1.0 (1.0-1.0) 　0.0045 1.0 (1.0-1.0) 0.068 0.97 (0.95-0.99) 　0.0009 0.97 (0.95-0.99) 0.0060
Triglyceride 1.0 (1.0-1.0) 　0.80 1.0 (1.0-1.0) 　0.39
HOMA-IR 1.0 (0.98-1.1) 　0.25 0.99 (0.96-1.0) 　0.62
†95% conﬁdence interval; PNPLA3,  patatin-like phospholipase domain-containing protein 3; LDL,  low-density lipoprotein; ALT,  alanine 
aminotransferase; γGT,  γ-glutamyl transpeptidase; HOMA-IR,  homeostasis model assessment insulin resistance.
among those with NVR (13/22).  On the other hand,  
34 of the patients with HCV genotype 2 (58.6ｵ) 
obtained SVR.  The stepwise logistic regression 
analysis on therapeutic outcomes for patients with 
HCV genotype 2 showed that the major allele of 
IL28B SNP was signiﬁcantly associated with SVR 
(p＝0.023).  Few patients showed NVR (4/58 (6.9ｵ)),  
and no predictive factors could be found for NVR.
Discussion
　 The present study focused on hepatic steatosis and 
its related SNPs in Japanese patients with CHC,  and 
clariﬁed the impact of factors aﬀecting hepatic steato-
sis on therapeutic outcomes.  The results revealed that 
severe hepatic steatosis is signiﬁcantly associated with 
NVR,  but not with SVR.  Severe hepatic steatosis 
was also signiﬁcantly associated with the minor alleles 
of IL28B SNP and with high BMI.  Our ﬁndings sug-
gest that the importance of IL28B SNP on the out-
comes of interferon therapy is associated with the 
severity of hepatic steatosis,  reﬂecting lipid metabolic 
disorder,  although the precise mechanism is unclear.  
It was reported that several SNPs around the IL28B 
were signiﬁcantly associated with therapeutic outcome.  
However,  these associations can be explained by a 
single SNP for Japanese patients,  because the major 
SNPs of rs8099917 and rs12979860 showed nearly 
identical results.  In terms of the SNPs of the LDL 
receptor,  genetic variants of LDL receptor have been 
shown to predict SVR to interferon therapy using a 
combination of several SNPs [16].  The SNP of the 
LDL receptor we examined in this study did not show 
any signiﬁcant associations with hepatic steatosis or 
the outcome of interferon therapy.  The analysis of 
diﬀerent SNPs in the LDL receptor might,  however,  
yield various associations with disease progression or 
prediction.
　 Recent studies on the SNP of PNPLA3 in patients 
with CHC revealed that the 148M genotype of 
PNPLA3 SNP is signiﬁcantly associated with hepatic 
steatosis due to its functional involvement in lipid 
metabolism; the inﬂuence of this SNP on SVR remains 
controversial,  however [17,  18].  The present study 
showed that the SNP genotypes of PNPLA3 have a 
weak association with severe hepatic steatosis,  but not 
with therapeutic outcomes for Japanese patients.  This 
diﬀerence might be due to the high prevalence of the 
risk allele of rs738409 of PNPLA3 in Japanese 
patients.  Prevalence of this risk allele was 50.2ｵ in 
the present study,  and 43ｵ in the Hap Map study,  
much higher than in Caucasians (23ｵ).  The ethnic 
diﬀerences in the prevalence of the SNP genotype 
might modulate the impacts of the SNP on hepatic 
steatosis or IFN therapeutic outcomes.
　 In conclusion,  hepatic steatosis was signiﬁcantly 
associated with the outcome of interferon therapy for 
Japanese patients with CHC.  As for the SNP sites 
examined in the present study,  an association was 
suggested between the SNP of IL28B and the outcome 
of interferon therapy,  but not the SNPs of PNPLA3 
or the LDL receptor.
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